

Status of Medical RI Production and Plan of Ac-225 Development in Indonesia

National Research and Innovation Agency
Nuclear Energy Research Organisation



BRIN
BADAN RISET
DAN INOVASI NASIONAL




INTRODUCTION

Herlan Setiawan

**Researcher in
Research Center for Radioisotope Radiopharmaceuticals and
Biodosimetry Technology**

- ✓ National Nuclear Energy Agency of Indonesia (BATAN) from 2011
- ✓ National Research and Innovation Agency (BRIN)

1st September 2021



LIPI
(Sciences
Institute)



batan
(Nuclear Agency)



BPPT
(Assessment Tech)



LAPAN
(Aeronautics
& Space)

**Other
Research
Institutes**




BRIN
BADAN RISET
DAN INOVASI NASIONAL



BRIN
BADAN RISET
DAN INOVASI NASIONAL

BRIN's Organization

Source: Presidential Decree 78/2021 about BRIN, Peraturan BRIN 1/2021 about BRIN's Organization





B

BADAN

DAN



INDONESIA



Tropical-Archipelago
~ 17,500 islands
(with 5 big islands)



➤ 81,000 km of coastline




➤ 285 Million of the population (4th)





BRIN
BADAN RISET
DAN INOVASI NASIONAL

Current Status of Nuclear Medicine Centers in Indonesia





BRIN
BAGAN RISET
DAN INOVASI NASIONAL

NUCLEAR ERA IN INDONESIA



1958 : National Nuclear Energy Agency (BATAN)

1965 : First research reactor in Indonesia (**Triga Mark**)
start-up in Bandung Nuclear Center (upgaraded to 2 MW)

1967 : First Nuclear Medicine Service located in Bandung

1979 : **“Kartini” Reactor** in Yogyakarta Nuclear Center (300 KW)

1987 : **Multipurpose Reactor “Siwabessy”** in Puspiptek Research Park
(Max ~30 MW) in Tangerang Selatan

1989 : Operation of Radioisotope and Radiopharmaceuticals
Production facilities (BATAN)

1996 : Radoisotop-Radiopharmaceuticals Company (PT Batan
Teknologi) (**transfer RIRR and Fuel Facility from BATAN**)

1997 : Establishment of a Nuclear Regulatory Agency (BAPETEN)

2013 : BATAN Build new facilities for RIRP Research (small scale
Production)

2014 : Batan Teknologi Company → PT Inuki (Industri Nuklir Indonesia)

2022 : BATAN join became part of BRIN

2023 : Inuki did not meet operational safety requirements (**STOP**)



BRIN
BADAN RISET
DAN INOVASI NASIONAL

Indonesia Research Reactor Status




TRIGA MARK II REACTOR

- Location: Bandung
- Operated in 1964, 250 kW
- Upgraded to 2000 kW in 2000
- Main Function: Isotope production and research
(Propose for decommissioning → update: reactivation)



KARTINI REACTOR (TRIGA MARK II)

- Location : Yogyakarta
- Operated in 1979, 100 kW
- Main Function : Research and Human Resource Training Facilities



G.A. SIWABESSY (GAS) MULTI-PURPOSE REACTOR

- Location : Serpong, Tangerang
- Operated in 1987, 30 → 15 → 5 MW
- Main Function : Isotope production and neutron research
- Revitalization Plan for Radioisotope Production Reactor



BRIN
BADAN RISET
DAN INOVASI NASIONAL


Utilizations of GAS-MPR Reactor

$^{99}\text{Mo}/^{99\text{m}}\text{Tc}$ (fission)
Generator


I-131
Ir-192



RI Production



Power Ramp Test



Neutron Beam
Research



Gemstones (topaz) Coloring




Neutron Activation Analysis




Neutron
Radiography

The configuration of Siwabessy Reactor core

Power	30 MW (Routine Op : 15 MW) → 5MW
Neutron Flux	$1.2-1.5 \times 10^{14} \text{ n/cm}^2 \cdot \text{s}$ $0.5-0.6 \times 10^{14} \text{ n/cm}^2 \cdot \text{s}$
Cooling Material	Light Water
Fuel Type	MTR
Fuel Material	$\text{U}_3\text{Si}_2\text{Al}$
^{235}U Enrichment	19.75 %
^{235}U Density	2.96 gr/cm ³
Absorber	Ag-In-Cd
Number of Control Rod	8
Reflector	Beryllium
Number of Neutron Beam	6
Radiation Protection Facility	Warm Water Layer



Radioisotope Production (for Research)



CIP capsule



Xenon loop for I-125 Production



Rabbit capsule

No	Radioisotope	Nuclear reaction	Target	Radiation
1	Sm-153	$^{152}\text{Sm} (n,\gamma) ^{153}\text{Sm}$	Sm_2O_3	β^- (694, 641 KeV) γ (103 KeV)
2	I-131	$^{130}\text{Te} (n,\gamma) ^{131}\text{Te} \rightarrow ^{131}\text{I}$	TeO_2	β^- (190 KeV) γ (606, 364, 248 KeV)
3	Mo-99	$^{98}\text{Mo} (n,\gamma) ^{99}\text{Mo}$	MoO_3	β^- (1215 KeV) γ (739 KeV)
4	Tc-99m	$^{98}\text{Mo} (n,\gamma) ^{99}\text{Mo} \rightarrow ^{99\text{m}}\text{Tc}$		γ (140 KeV)
5	P-32	$^{32}\text{S} (n,p) ^{32}\text{P}$	Sulfur	β^- (1710 KeV)
6	Ir-192	$^{191}\text{Ir} (n,\gamma) ^{192}\text{Ir}$	Ir wire	β^- (208, 160 KeV) γ (316, 468, 308.. KeV)
7	Au-198	$^{197}\text{Au} (n,\gamma) ^{198}\text{Au}$	Au foil	β^- (961, 285 KeV) γ (411 KeV)
8	Lu-177	$^{176}\text{Lu} (n,\gamma) ^{177}\text{Lu}$ $^{176}\text{Yb} (n,\gamma) ^{177}\text{Yb} \rightarrow ^{177}\text{Lu}$	$\text{Lu}_2\text{O}_3 / \text{Yb}_2\text{O}_3$	β^- (496, 175 KeV) γ (208, 112, KeV)
9	Ho-166	$^{165}\text{Ho} (n,\gamma) ^{166}\text{Ho}$	$\text{Ho}_2\text{O}_3 / \text{Dy}_2\text{O}_3$	β^- (1773, 1854 KeV) γ (80 KeV)
10	Gd-153	$^{152}\text{Gd} (n,\gamma) ^{153}\text{Gd}$	Gd_2O_3	γ (76 KeV)
11	Sc-45	$^{45}\text{Sc} (n,\gamma) ^{46}\text{Sc}$	$\text{Sc}_2\text{O}_3 / \text{Sc foil}$	β^- (111 KeV) γ (889, 1120 KeV)
12	I-125	$^{124}\text{Xe} (n,\gamma) ^{125}\text{Xe} \rightarrow ^{125}\text{I}$	Xe gas	γ (35 KeV)

RESEARCH CENTER FOR RADIOISOTOPE AND RADIOPHARMACEUTICALS TECHNOLOGY (BATAN)



Build in 2013-2017



Research facilities for Radioisotope and Radiopharmaceuticals Development



GMP facilities for Radiopharmaceutical Cold-kit Production



Hot-lab for Radionuclide and Labelled Compound Production



BRIN
BANDAR RISET
DAN INOVASI NASIONAL



Renalscan KaeF
(DTPA)



Bonescan KaeF
(MDP)



TB-scan
(Ethambutol Kit)

2021

2022



2016



T-Bone KaeF
(^{153}Sm -EDTMP)



Endoneuroscan KaeF
(^{131}I -MIBG)



BRIN

Reactor Operation Schedule

OPERATION AND MAINTENANCE SCHEDULE OF RSG-GAS 2019
Rev. 0 (December 26, 2018)

2019

OPERATION AND MAINTENANCE SCHEDULE OF RSG-GAS 2021
REV. 0 (Des 04, 2020)

2021

OPERATION AND MAINTENANCE SCHEDULE OF RSG-GAS 2023
REV.2 (August 7, 2023)

2023

OPERATION AND MAINTENANCE SCHEDULE OF RSG-GAS 2024
REV.3 (06 Agustus 2024)

on 5 MW
2024
DT


2025

DRAFT OPERATION AND MAINTENANCE SCHEDULE OF RSG-GAS 2025
REV.1 (26 NOVEMBER 2025)

TT ELEKTRONIK


TT ELEKTRONIK

OPEN ELEKTRONIK



Directorate of Nuclear Energy Facilities Management

Location : KST BJ Habibie, Tangerang Selatan





BRIN
BADAN RISET
DAN INOVASI NASIONAL

Ac-225 Radiopharmaceuticals: Emerging Potentials and Challenges in Indonesia”

- CRP F22075 : Production and Quality Control of Ac-225 radiopharmaceuticals
- RC26334 : Production and Quality Control of (Ac-225) Ac-PSMA-I&T for Treatment of Prostate Cancer in Indonesia

Emerging Potentials In Indonesia

Indonesia's/ **BRIN** infrastructure (reactors, radiopharmacy labs) provides a foundation.

- **Opportunities:**
 - Local production of Ac-225 from Th-229 decay or Ra-226 targets.
 - Research collaboration with hospitals and universities for clinical trials.
 - Development of indigenous ligands suited to local cancer prevalence.
 - Could position Indonesia as a regional hub for alpha therapy radiopharmaceuticals.



BRIN
BADAN RISET
DAN INOVASI NASIONAL

Ac-225 Radiopharmaceuticals: “Emerging Potentials and Challenges in Indonesia”

Challenges :

Aspect	Challenges
Production	<ul style="list-style-type: none">• Limited access to parent isotopes (Th-229, Ra-226); lack of high-energy accelerators.• Based on BRIN Waste management : 4.7 Ci (Ra-226 seal in SS capsule) 4.0 Ci (Ra-226 not yet conditioned)
Radiochemistry	<ul style="list-style-type: none">• Complex handling of alpha emitters; need for shielded hot cells and advanced chelation chemistry.
Regulation & Safety	<ul style="list-style-type: none">• High radiotoxicity requires strict handling, waste management, and dosimetry protocols.
Clinical Translation	<ul style="list-style-type: none">• Need for trained personnel, GMP facilities, and ethical approval pathways.
Economic Feasibility	<ul style="list-style-type: none">• High initial investment; uncertain reimbursement and market size.



Facilities prepared for the synthesis of radiopharmaceutical Ac-225

CONCLUSION

- Currently, all radioisotopes and radiopharmaceuticals in Indonesia are imported.
- Revitalization of existing nuclear facilities is very important for reactor operations, especially for the production of radioisotopes and radiopharmaceuticals in Indonesia.
- Strategic investment, capacity building, and international cooperation are key to success.
- Ac-225 radiopharmaceuticals represent a transformative leap in nuclear medicine.
- With proper planning, Indonesia could become a leader in alpha-based targeted therapy in Southeast Asia.

Terima Kasih

Thank You ありがとう
감사합니다 Рақмет сізге

